Tempus AI, Inc. (NASDAQ:TEM) Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC grew its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 37.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,174 shares of the company’s stock after buying an additional 23,070 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Tempus AI were worth $2,842,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in Tempus AI during the 4th quarter worth $372,000. Dakota Wealth Management boosted its position in shares of Tempus AI by 189.7% in the fourth quarter. Dakota Wealth Management now owns 60,668 shares of the company’s stock worth $2,048,000 after buying an additional 39,724 shares during the period. Avanza Fonder AB acquired a new stake in shares of Tempus AI in the fourth quarter valued at about $1,197,000. Bouvel Investment Partners LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at about $1,029,000. Finally, FNY Investment Advisers LLC acquired a new position in Tempus AI during the 4th quarter worth approximately $67,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insiders Place Their Bets

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares in the company, valued at $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $53.39, for a total value of $4,580,221.32. Following the sale, the chief executive officer now owns 5,771,787 shares in the company, valued at $308,155,707.93. The trade was a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862,758 shares of company stock valued at $79,585,675 over the last 90 days.

Analyst Ratings Changes

Several brokerages have issued reports on TEM. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Guggenheim began coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Bank of America increased their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Tempus AI Trading Down 6.3 %

Shares of TEM opened at $51.40 on Friday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock has a 50 day moving average of $44.36 and a 200-day moving average of $47.68.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.